Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche's RoActemra is better than Abbot's Humira, says Scotland, but Zelboraf fails to impress

This article was originally published in Scrip

Executive Summary

Head to head data comparing Roche's RoActemra (tocilizumab) and Abbott's Humira (adalimumab) has convinced Scotland's health technology appraisal body, the Scottish Medicines Consortium, to approve RoActemra for use on the Scottish NHS as a monotherapy for rheumatoid arthritis patients. Nevertheless, Roche is complaining about the SMC's methods for appraising end-of-life cancer drugs, after it said no to Zelboraf (vemurafenib) for metastatic melanoma patients, which Roche claims is now the standard of care in England.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts